Table 3.
| a: International Prognostic Scoring system | |||||
|---|---|---|---|---|---|
| Prognostic Variable | 0 | 0.5 | 1.0 | 1.5 | 2.0 |
| BM Blasts (%) | <5 | 5–10 | − | 11–20 | 21–30 |
| Karyotype | Good | Intermediate | Poor | ||
| Cytopenias* | 0/1 | 2/3 | |||
| Risk group | IPSS score | Median Survival (yrs) |
Time until 25% of patients developed AML (yrs) |
|---|---|---|---|
| Low | 0 | 5.7 | 9.4 |
| Intermediate-1 | 0.5–1.0 | 3.5 | 3.3 |
| Intermediate-2 | 1.5–2.0 | 1.2 | 1.1 |
| High | ≥ 2.5 | 0.4 | 0.2 |
| b. Cytogenetic Abnormalities in the International Prognosis Scoring System | ||||
|---|---|---|---|---|
| Cytogenetic Abnormalities |
Time until 25% of pts developed AML (mos) |
Median Survival | ||
| Favorable risk | normal karyotype | 5.6 years | 3.8 years | |
| isolated del(5q) | ||||
| isolated del(20q) | ||||
| isolated –Y | ||||
| Intermediate risk | other abnormalities | 1.6 years | 2.4 years | |
| Poor risk | −7/del(7q) | 0.9 years | 0.8 years | |
| complex kayotypes | ||||
*
Cytopenias were defined as: Hemoglobin < 10 g/dL, ANC < 1500/uL, Platelet count < 100,000/ L.